1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 6 1.2 List of Figures 7 2 Introduction 9 2.1 Disease Introduction 9 2.2 Epidemiology 9 2.3 Symptoms 10 2.4 Etiology and Pathophysiology 10 2.5 Diagnosis 11 2.6 Classification 12 2.7 Treatment Guidelines and Options 13 2.7.1 ICS Monotherapy for the Maintenance Treatment of Asthma 16 2.7.2 Montelukast sodium as First-Line Maintenance Therapy 19 2.7.3 ICS/LABA Combination Therapy 20 2.7.4 Add-on Therapies 25 3 Marketed Products 30 3.1 Overview 30 3.2 ICS for the Maintenance Treatment of Asthma 30 3.2.1 Arnuity (fluticasone furoate) 30 3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma 31 3.3.1 Seretide/Adoair (fluticasone propionate and salmeterol xinafoate) - GlaxoSmithKline 31 3.3.2 Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-Promotion with Astellas Pharma 32 3.3.3 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) - GlaxoSmithKline 33 3.3.4 Flutiform (fluticasone propionate and formoterol fumarate) - SkyePharma 34 3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma 35 3.4.1 Xolair (omalizumab) - Novartis and Genentech 35 3.4.2 Montelukast sodium 36 3.4.3 Spiriva (tiotropium bromide) - Boehringer Ingelheim 37 3.5 Comparative Efficacy and Safety of Marketed Products 38 4 Pipeline Analysis 41 4.1 Overview 41 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 41 4.3 Pipeline by Molecular Target 43 4.4 Promising Pipeline Molecules 47 4.4.1 Mepolizumab - GlaxoSmithKline 47 4.4.2 Reslizumab - Teva Pharmaceutical 49 4.4.3 Lebrikizumab - Roche/Genentech 51 4.4.4 Dupilumab - Regeneron Pharmaceuticals in Collaboration with Sanofi 52 4.4.5 Tralokinumab - AstraZeneca 55 4.4.6 Benralizumab - AstraZeneca 56 4.5 Comparative Efficacy and Safety of Pipeline Products 58 5 Clinical Trial Analysis 62 5.1 Failure Rate 62 5.1.1 Overall Failure Rate 62 5.1.2 Failure Rate by Phase and Molecule Type 63 5.1.3 Failure Rate by Phase and Molecular Target 64 5.2 Clinical Trial Size 65 5.2.1 Patient Enrollment per Product by Stage of Development by Molecule Type and Molecular Target 65 5.2.2 Patient Enrollment per Trial by Stage of Development by Molecule Type and Molecular Target 67 5.3 Clinical Trial Duration 69 5.3.1 Trial Duration by Stage of Development by Molecule Type and Molecular Target 69 5.4 Summary of Clinical Trial Metrics 70 6 Multi-Scenario Forecast 72 6.1 Geographical Markets 72 6.2 Asia-Pacific Market 73 6.3 India 75 6.3.1 Treatment Usage Patterns 75 6.3.2 Annual Cost of Therapy 76 6.3.3 Market Size 76 6.4 China 77 6.4.1 Treatment Usage Patterns 77 6.4.2 Annual Cost of Therapy 78 6.4.3 Market Size 79 6.5 Australia 80 6.5.1 Treatment Usage Patterns 80 6.5.2 Annual Cost of Therapy 81 6.5.3 Market Size 82 6.6 South Korea 83 6.6.1 Treatment Usage Patterns 83 6.6.2 Annual Cost of Therapy 84 6.6.3 Market Size 85 6.7 Japan 86 6.7.1 Treatment Usage Patterns 86 6.7.2 Annual Cost of Therapy 87 6.7.3 Market Size 88 7 Drivers and Barriers 90 7.1 Drivers 90 7.1.1 Rising Prevalence 90 7.1.2 New Costly Market Entries 90 7.1.3 Growing Alternative Therapeutic Choices 90 7.2 Barriers 90 7.2.1 Usage of Traditional Medicines 90 7.2.2 Treatment Regimen Adherence 91 7.2.3 Limited Understanding of Underlying Causes 91 7.2.4 Lack of Awareness and Affordability of High-Cost Biological Products 91 8 Deals and Strategic Consolidations 92 8.1 Co-development Deals 92 8.1.1 Deals by Region and Value 92 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 93 8.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target 94 8.1.4 Key Co-Development Deals 97 8.2 Licensing Deals 99 8.2.1 Deals by Region and Value 99 8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 100 8.2.3 Deal Value by Stage of Development, Molecule Type and Molecular Target 100 8.2.4 Key Licensing Deals 103 9 Appendix 106 9.1 All Pipeline Drugs by Phase of Development 106 9.1.1 Discovery 106 9.1.2 Preclinical 107 9.1.3 Phase I 112 9.1.4 Phase II 113 9.1.5 Phase III 115 9.1.6 Pre-registration 116 9.2 Summary of Multi-Scenario Market Forecasts to 2021 116 9.2.1 Asia-Pacific 116 9.2.2 China 117 9.2.3 India 117 9.2.4 Australia 118 9.2.5 South Korea 118 9.2.6 Japan 119 9.3 References 119 9.4 Abbreviations 124 9.5 Research Methodology 126 9.5.1 Secondary Research 127 9.5.2 Marketed Product Profiles 127 9.5.3 Late-Stage Pipeline Candidates 127 9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 128 9.5.5 Product Competitiveness Framework 128 9.5.6 Pipeline Analysis 128 9.5.7 Forecasting Model 129 9.5.8 Deals Data Analysis 130 9.6 Contact Us 130 9.7 Disclaimer 130

1.1 List of Tables Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity According to GINA Guidelines (2002) 12 Table 2: Asthma Therapeutics, Global, Management of Chronic Asthma in Adults and Children above Five Years 14 Table 3: Asthma Diagnosis, Global, Symptoms and Management of Acute Asthma 15 Table 4: Asthma Trials, Global, Clinical Trial Endpoints 16 Table 5: Asthma Therapeutics, Global, All Pipeline Products, Discovery, 2015 106 Table 6: Asthma Therapeutics, Global, All Pipeline Products, Preclinical, 2015 107 Table 7: Asthma Therapeutics, Global, All Pipeline Products, Phase I, 2015 112 Table 8: Asthma Therapeutics, Global, All Pipeline Products, Phase II, 2015 113 Table 9: Asthma Therapeutics, Global, All Pipeline Products, Phase III, 2015 115 Table 10: Asthma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2015 116 Table 11: Asthma Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021 116 Table 12: Asthma Therapeutics Market, China, Market Forecast, 2014-2021 117 Table 13: Asthma Therapeutics Market, India, Market Forecast, 2014-2021 117 Table 14: Asthma Therapeutics Market, Australia, Market Forecast, 2014-2021 118 Table 15: Asthma Therapeutics Market, South Korea, Market Forecast, 2014-2021 118 Table 16: Asthma Therapeutics Market, Japan, Market Forecast, 2014-2021 119 1.2 List of Figures Figure 1: Asthma Therapeutics Market, Asia-Pacific, Heat Map for Marketed Products, 2015 38 Figure 2: Asthma Therapeutics Market, Asia-Pacific, Heat Map for Marketed Products (continued), 2015 39 Figure 3: Asthma Therapeutics Market, Global, Pipeline, 2015 43 Figure 4: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, 2015 46 Figure 5: Asthma Therapeutics Market, Asia-Pacific, Mepolizumab Forecast ($m), 2016-2021 49 Figure 6: Asthma Therapeutics Market, Asia-Pacific, Reslizumab Forecast ($m), 2016-2021 51 Figure 7: Asthma Therapeutics Market, Asia-pacific, Lebrikizumab Forecast ($m), 2018-2021 52 Figure 8: Asthma Therapeutics Market, Asia-Pacific, Dupilumab Forecast ($m), 2019-2021 55 Figure 9: Asthma Therapeutics Market, Asia-Pacific, Tralokinumab Forecast ($m), 2019-2021 56 Figure 10: Asthma Therapeutics Market, Asia-Pacific, Benralizumab Forecast ($m), 2020-2021 58 Figure 11: Asthma Therapeutics Market, Global, Heat Map for Pipeline Products, 2015 59 Figure 12: Asthma Therapeutics Market, Global, Competitor Matrix for Marketed and Pipeline Products, 2015 60 Figure 13: Asthma Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2015 63 Figure 14: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2015 64 Figure 15: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2015 65 Figure 16: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2015 66 Figure 17: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecular Target, 2006-2015 67 Figure 18: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecule Type, 2006-2015 68 Figure 19: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecular Target, 2006-2015 68 Figure 20: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006-2015 69 Figure 21: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecular Target, 2006-2015 70 Figure 22: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 70 Figure 23: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 71 Figure 24: Asthma Therapeutics Market, Asia-Pacific, Treatment Patterns, 2014-2021 73 Figure 25: Asthma Therapeutics Market, Asia-Pacific, Market Size ($bn), 2014-2021 74 Figure 26: Asthma Therapeutics Market, India, Treatment Patterns, 2014-2021 75 Figure 27: Asthma Therapeutics Market, India, Annual Cost of Therapy ($), 2014-2021 76 Figure 28: Asthma Therapeutics Market, India, Market Size, 2014-2021 77 Figure 29: Asthma Therapeutics Market, China, Treatment Patterns, 2014-2021 78 Figure 30: Asthma Therapeutics Market, China, Annual Cost of Therapy ($), 2014-2021 79 Figure 31: Asthma Therapeutics Market, China, Market Size, 2014-2021 80 Figure 32: Asthma Therapeutics Market, Australia, Treatment Patterns, 2014-2021 81 Figure 33: Asthma Therapeutics Market, Australia, Annual Cost of Therapy ($), 2014-2021 82 Figure 34: Asthma Therapeutics Market, Australia, Market Size, 2014-2021 83 Figure 35: Asthma Therapeutics Market, South Korea, Treatment Patterns, 2014-2021 84 Figure 36: Asthma Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2014-2021 85 Figure 37: Asthma Therapeutics Market, South Korea, Market Size, 2014-2021 86 Figure 38: Asthma Therapeutics Market, Japan, Treatment Patterns, 2014-2021 87 Figure 39: Asthma Therapeutics Market, Japan, Annual Cost of Therapy ($), 2014-2021 88 Figure 40: Asthma Therapeutics Market, Japan, Market Size ($bn), 2014-2021 89 Figure 41: Asthma Therapeutics Market, Global, Co-Development Deals by Region, 2006-2015 92 Figure 42: Asthma Therapeutics Market, Global, Co-Development Deals by Value ($m), 2006-2015 93 Figure 43: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-Development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2015 94 Figure 44: Asthma Therapeutics Market, Global, Co-Development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015 95 Figure 45: Asthma Therapeutics Market, Global, Co-Development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015 96 Figure 46: Asthma Therapeutics Market, Global, Co-Development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2015 97 Figure 47: Asthma Therapeutics Market, Global, Licensing Deals by Region, 2006-2015 99 Figure 48: Asthma Therapeutics Market, Global, Licensing Deals by Value ($m), 2006-2015 99 Figure 49: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2015 100 Figure 50: Asthma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015 101 Figure 51: Asthma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015 102 Figure 52: Asthma Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2015 103